ibex_ai

Ibex is a pioneering company transforming cancer diagnostics through the power of artificial intelligence. Since its inception in 2016, Ibex has established itself as the most widely-deployed AI platform in pathology, developed by pathologists for pathologists. Its core mission is to ensure every patient receives an accurate, timely, and personalized cancer diagnosis. The platform serves leading physicians, healthcare organizations, and diagnostic providers globally, enhancing diagnostic quality, streamlining workflows, and ultimately improving patient outcomes.

The Ibex platform leverages sophisticated deep learning algorithms trained on massive, diverse datasets, including over 10 million pathology slides. This extensive training enables the AI to detect not only cancer but also over a hundred other clinically relevant features in multiple tissue types, such as breast, prostate, and gastric biopsies. The technology has received FDA 510(k) clearance and is clinically proven to deliver real-world impact, raising physician confidence and ensuring a higher standard of care.

How to use ibex_ai

Integrating Ibex into a clinical setting is designed to be seamless and complementary to the existing digital pathology workflow. The process typically involves the following steps:1. Digital Slide Acquisition: A pathologist or lab technician uses a digital slide scanner to create a high-resolution whole-slide image (WSI) of a patient's tissue sample (e.g., a biopsy).

2. AI Analysis: The WSI is uploaded to the Ibex platform, which integrates with the laboratory's information system (LIS) and image management software. The AI algorithms automatically analyze the entire slide in minutes.

3. Review and Insights: The platform presents the analysis to the pathologist. It highlights suspicious areas, pre-classifies slides, and provides a comprehensive report with key findings. This includes cancer detection, Gleason grading for prostate cancer, tumor sizing, perineural invasion detection, and biomarker scoring (like HER2).

4. Pathologist's Final Diagnosis: The pathologist uses the AI's insights as a 'second read' or a 'digital assistant'. They review the AI-flagged areas, confirm the findings, and make the final, definitive diagnosis. The AI acts as a powerful quality control tool, ensuring that even small, hard-to-detect cancerous foci are not missed.

Core Features of ibex_ai

• Multi-Tissue Cancer Detection: AI-powered solutions for the accurate diagnosis of breast, prostate, and gastric cancers.
• Comprehensive Feature Identification: Detects over 100 other clinically significant features beyond cancer, providing a holistic diagnostic picture.
• Advanced Prostate Diagnostics: Includes precise Gleason grading, tumor sizing, and detection of perineural invasion.
• In-depth Breast Cancer Analysis: Offers insights into the type of invasive carcinomas, nuclear grading of in situ carcinomas, and improved HER2 biomarker scoring.
• Clinically-Proven Accuracy: Validated in multiple studies with near-perfect concordance with pathologist consensus and has received FDA clearance.
• Workflow Integration: Seamlessly integrates with existing digital pathology scanners, LIS, and PACS systems from partners like Philips and FUJIFILM.
• AI-Powered Quality Control: Acts as a vigilant second pair of eyes, helping to reduce diagnostic errors and increase confidence.

Use Cases for ibex_ai

Ibex is deployed in leading hospitals, laboratories, and health systems worldwide to enhance various aspects of the diagnostic workflow.

• Primary Diagnosis: Pathologists use Ibex as a primary diagnostic aid to improve efficiency and accuracy, allowing them to focus on complex cases while the AI handles initial screening.
• Quality Assurance: The platform serves as a prospective quality control measure, automatically reviewing cases to catch potential misses, especially for small or high-grade cancers.
• Second-Opinion Consultation: It provides an instant, data-driven 'second opinion', helping pathologists confirm their findings and increase diagnostic confidence, particularly in challenging cases.
• Standardizing Care: By providing objective and reproducible analysis, Ibex helps standardize the quality of diagnosis across different pathologists and institutions. For example, prestigious centers like Institut Curie in Paris use Ibex to enhance their diagnostic capabilities.

Advantages of ibex_ai

The adoption of Ibex brings significant advantages to pathology labs and patient care. Its primary strengths are:

• Enhanced Quality and Accuracy: Dramatically reduces the risk of missed diagnoses and improves the accuracy of grading and staging.
• Improved Efficiency: Automates repetitive tasks and prioritizes cases, leading to faster turnaround times and optimized workflows.
• Increased Pathologist Confidence: Provides a reliable safety net, empowering pathologists to make diagnoses with greater certainty.
• Trusted and Proven: Developed in collaboration with pathologists and validated through extensive clinical studies and real-world deployments.
• Better Patient Outcomes: More accurate and timely diagnoses lead directly to better treatment decisions and improved patient care.

Pricing and Plans

Ibex offers enterprise-level solutions tailored to the specific needs of hospitals, diagnostic laboratories, and healthcare systems. Pricing is customized based on the scale of deployment, required modules (e.g., Breast, Prostate), and integration needs. To get detailed pricing information, interested organizations should contact the Ibex sales team directly to schedule a demo and receive a custom quote.